Identification of sestrin3 involved in the in vitro resistance of colorectal cancer cells to irinotecan

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acquire chronic resistance to irinotecan. We profiled their differential gene expression using microarray. After gene ontology (GO) and KEGG pathway analysis of the microarray data, we specifically investigated whether Sestrin3 could decrease irinotecan resistance. Our results revealed that Sestrin3 enhanced the anticancer effect of irinotecan in vitro in LoVo cells that had acquired resistance to irinotecan. Irinotecan-resistant LoVo cells showed lower reactive oxygen species (ROS) production than their irinotecan-sensitive parental cells. ROS production was increased by Sestrin3 knockdown in irinotecan-resistant LoVo cells. Our results indicate that Sestrin3 might be a good target to develop therapeutics that can help to overcome resistance to irinotecan.

Cite

CITATION STYLE

APA

Choi, S. H., Hong, H. K., Cho, Y. B., Lee, W. Y., & Yoo, H. Y. (2015). Identification of sestrin3 involved in the in vitro resistance of colorectal cancer cells to irinotecan. PLoS ONE, 10(5). https://doi.org/10.1371/journal.pone.0126830

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free